Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06345755

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial

Official title:
A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of VX-407 in Healthy Subjects

Clinical Trial Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.

Clinical Trial Description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06345755
Study type Interventional
Source Vertex Pharmaceuticals Incorporated
Contact Medical Information
Phone 617-341-6777
Email medicalinfo@vrtx.com
Status Recruiting
Phase Phase 1
Start date April 17, 2024
Completion date April 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02964273 - Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) Phase 3
Terminated NCT01223755 - Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency Phase 2/Phase 3
Completed NCT01280721 - A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] Phase 3
Completed NCT01214421 - Tolvaptan Extension Study in Participants With ADPKD Phase 3
Completed NCT02225860 - Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease Phase 2/Phase 3
Active, not recruiting NCT01616927 - Study of Lanreotide to Treat Polycystic Kidney Disease Phase 3
Completed NCT01430494 - Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT00346918 - Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT03949894 - Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease Phase 4
Recruiting NCT02925221 - Canadian Medical Assessment of JINARC™ Outcomes Registry
Completed NCT04689074 - Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
Terminated NCT02616055 - Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 Phase 2
Recruiting NCT06289998 - Study of Tamibarotene in Patients With ADPKD Phase 2
Completed NCT02112136 - Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD N/A
Recruiting NCT02115659 - Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT00309283 - Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study Phase 3